文献速递白血病

非必需氨基酸半胱氨酸是防止急性髓系白血病细胞铁死亡所必需的

The nonessential amino acid cysteine is required to prevent ferroptosis in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

本文报道白血病干/祖细胞对半胱氨酸耗竭广泛敏感,通过CRISPR/Cas9敲除胱硫醚-γ-裂解酶及上游代谢物补充实验证实急性髓系白血病(AML)细胞不能由甲硫氨酸合成半胱氨酸。半胱氨酸耗竭升高活性氧(ROS)并主要通过剥夺谷胱甘肽诱导铁死亡,抑制烟酰胺腺嘌呤二核苷酸磷酸氧化酶可挽救细胞活力。抑制谷胱甘肽过氧化物酶4(GPX4)或硫氧还蛋白还原酶同样损害细胞活力,氧化磷酸化驱动的AML亚型尤其依赖硫氧还蛋白介导的抗铁死亡保护;柳氮磺吡啶单药无效,与L-丁硫氨酸亚砜亚胺(BSO)联用可增强铁死亡诱导。

要点

  • AML细胞不能由甲硫氨酸合成半胱氨酸,必须外源摄取半胱氨酸才能存活。
  • 半胱氨酸耗竭经谷胱甘肽剥夺升高ROS,主要以铁死亡方式诱导AML细胞死亡。
  • 氧化磷酸化驱动的AML亚型高度依赖硫氧还蛋白介导的抗铁死亡保护。

核心结论

  • 半胱氨酸虽在营养上可能属非必需,但AML细胞必须摄取半胱氨酸才能存活,其耗竭主要通过谷胱甘肽剥夺升高ROS并诱导铁死亡。
  • 作者提出GPX4可能关键介导谷胱甘肽的抗氧化活性,氧化磷酸化驱动的AML亚型尤其依赖硫氧还蛋白介导的抗铁死亡保护。
  • 作者建议将柳氮磺吡啶或抗氧化机制抑制剂与BSO或化疗等ROS诱导剂联用,以供进一步临床前测试。

研究设计与样本

  • 研究采用CRISPR/CRISPR关联蛋白9介导的胱硫醚-γ-裂解酶敲除及半胱氨酸上游代谢物补充实验,并在AML细胞中开展功能验证。
  • 研究比较了半胱氨酸耗竭后烟酰胺腺嘌呤二核苷酸磷酸氧化酶抑制、GPX4抑制、硫氧还蛋白还原酶抑制及柳氮磺吡啶单药或与BSO联用的效应。

主要发现

  • 白血病干/祖细胞对半胱氨酸耗竭广泛敏感,胱硫醚-γ-裂解酶敲除及上游代谢物补充实验功能证明AML细胞不能由甲硫氨酸合成半胱氨酸。
  • 半胱氨酸耗竭升高ROS水平,细胞死亡主要因谷胱甘肽剥夺而诱导,烟酰胺腺嘌呤二核苷酸磷酸氧化酶抑制可强烈挽救半胱氨酸耗竭后的细胞活力。
  • ROS诱导的细胞死亡通过铁死亡介导,抑制GPX4亦高度有毒。
  • 用金诺芬抑制ROS清除剂硫氧还蛋白还原酶同样损害细胞活力,氧化磷酸化驱动的AML亚型尤其高度依赖硫氧还蛋白介导的抗铁死亡保护。
  • 柳氮磺吡啶单药抑制胱氨酸-谷氨酰胺反向转运体无效,但与BSO联用进一步改善AML铁死亡诱导。

临床怎么用

  • 作者提出将柳氮磺吡啶或抗氧化机制抑制剂与BSO或化疗等ROS诱导剂联用,以供进一步临床前测试。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cysteine is a nonessential amino acid required for protein synthesis, the generation of the antioxidant glutathione, and for synthesizing the nonproteinogenic amino acid taurine. Here, we highlight the broad sensitivity of leukemic stem and progenitor cells to cysteine depletion. By CRISPR/CRISPR-associated protein 9-mediated knockout of cystathionine-γ-lyase, the cystathionine-to-cysteine converting enzyme, and by metabolite supplementation studies upstream of cysteine, we functionally prove that cysteine is not synthesized from methionine in acute myeloid leukemia (AML) cells. Therefore, although perhaps nutritionally nonessential, cysteine must be imported for survival of these specific cell types. Depletion of cyst(e)ine increased reactive oxygen species (ROS) levels, and cell death was induced predominantly as a consequence of glutathione deprivation. nicotinamide adenine dinucleotide phosphate hydrogen oxidase inhibition strongly rescued viability after cysteine depletion, highlighting this as an important source of ROS in AML. ROS-induced cell death was mediated via ferroptosis, and inhibition of glutathione peroxidase 4 (GPX4), which functions in reducing lipid peroxides, was also highly toxic. We therefore propose that GPX4 is likely key in mediating the antioxidant activity of glutathione. In line, inhibition of the ROS scavenger thioredoxin reductase with auranofin also impaired cell viability, whereby we find that oxidative phosphorylation-driven AML subtypes, in particular, are highly dependent on thioredoxin-mediated protection against ferroptosis. Although inhibition of the cystine-glutamine antiporter by sulfasalazine was ineffective as a monotherapy, its combination with L-buthionine-sulfoximine (BSO) further improved AML ferroptosis induction. We propose the combination of either sulfasalazine or antioxidant machinery inhibitors along with ROS inducers such as BSO or chemotherapy for further preclinical testing.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cunningham A, Oudejans LL, Geugien M, et al. The nonessential amino acid cysteine is required to prevent ferroptosis in acute myeloid leukemia. Blood Adv. 2024. PMID: 37906522. doi:10.1182/bloodadvances.2023010786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。